AstraZeneca Results Presentation Deck
Calquence and Enhertu
Strong launch trajectories continue
$m
450
400
350
300
250
200
150
100
50
0
Calquence: 136% growth to $1.2bn
Approvals/Reimbursements: 76/25 (CLL), 37/13 (MCL)
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2019
2020
US Europe EROW EM
2021
• Global $1,238m; US $1,089m
•
●
US CLL
Strong performance with 54%
share of new patients starts
Global CLL
Continued launch performance in
DE, UK, FR and International
markets
• US MCL
Preferred BTKI in relapsed
refractory MCL
CALQUENCE
calenutrits caps
100 mg
$m
80
70
60
50
40
30
20
10
Enhertu: 123% growth to $214m
Approvals/Reimbursements: 9/4 (mBC), 4/2 (GC)
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2019
US Europe EROW EM
2020
2021
●
●
●
●
Global $214m; US $169m
Total in-market sales ex-Japan:
$426m
US
#1 in 3rd-line HER2+ mBC,
continuing launch in 2nd-line GC,
NCCN and ESMO guidelines for
2nd-line mBC
Global
Strong launches in
France and UK
19 CLL chronic lymphocytic leukaemia; MCL = mantle cell lymphoma; BTKI = Bruton tyrosine kinase inhibitor; GC = gastric cancer; 3L = 3rd-line; NCCN = National Comprehensive Cancer Network; ESMO = European Society for Medical
Oncology.
C
ENHERTU
(lam rasturnab denotecan-mok)
For Injection
100 mg per vial
Only
For
inge
P
T
KEEP REFRIGERATED
Perry
www.
de
Daichi Sankyo AdtraZenecaView entire presentation